Vesugen (Lys-Glu-Asp) (20 mg Vial) Dosage Protocol

Plan based on an 8–16 week daily protocol with gradual titration (targeting ~1500 mcg/day maintenance).

• Peptide Vials (Vesugen, 20 mg each):
  • 8 weeks (~84 mg total) ≈ 5 vials
  • 12 weeks (~126 mg total) ≈ 7 vials
  • 16 weeks (~168 mg total) ≈ 9 vials
• Insulin Syringes (U-100):
  • Per week: 7 syringes (1/day)
  • 8 weeks: 56 syringes
  • 12 weeks: 84 syringes
  • 16 weeks: 112 syringes
• Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
  • 8 weeks (5 vials): 15 mL → 2 × 10 mL bottles
  • 12 weeks (7 vials): 21 mL → 3 × 10 mL bottles
  • 16 weeks (9 vials): 27 mL → 3 × 10 mL bottles
• Alcohol Swabs: One for the vial stopper + one for the injection site each day.
  • Per week: 14 swabs (2/day)
  • 8 weeks: 112 swabs → recommend 2 × 100-count boxes
  • 12 weeks: 168 swabs → recommend 2 × 100-count boxes
  • 16 weeks: 224 swabs → recommend 3 × 100-count boxes

Vesugen (Lys-Glu-Asp) 20 mg

View Supplier

U-100 syringes

View Supplier

Bacteriostatic water

View Supplier

Alcohol swabs

View Supplier

PeptideDosages has no affiliation with Pure Lab Peptides and receives no commission from these Pure Lab links. Supplier pages are not scientific evidence or proof of suitability for human use.

• Reconstitute: Add 3.0 mL bacteriostatic water → ~6.67 mg/mL concentration.
• Typical daily range: 500–2000 mcg once daily (gradual titration).
• Easy measuring: At 6.67 mg/mL, 1 unit = 0.01 mL ≈ 66.7 mcg on a U-100 insulin syringe.
• Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.

Vesugen (Lys-Glu-Asp, also known as KED) is a tripeptide bioregulator synthesized at the Saint Petersburg Institute of Bioregulation and Gerontology^[1]. Research suggests it may support vascular endothelial cell proliferation through epigenetic regulation of Ki-67 gene expression^[2]. This educational protocol presents a once-daily subcutaneous approach using a practical dilution for clear insulin-syringe measurements.

Concise summary of the once-daily regimen.

• Goal: Support vascular endothelial function and cellular renewal over time^[2].
• Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
• Dose Range: 500–2000 mcg daily with gradual titration.
• Reconstitution: 3.0 mL per 20 mg vial (~6.67 mg/mL) for accurate unit measurements.
• Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.

Suggested daily titration approach.

• Start: 500 mcg daily; increase by ~500 mcg weekly as tolerated.
• Target: 1500–2000 mcg daily by Weeks 3–8+.
• Frequency: Once per day (subcutaneous).
• Cycle Length: 8–12 weeks; optional extension to 16 weeks.
• Timing: Any consistent time; rotate injection sites.

Proper storage preserves peptide quality^[10].

• Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); prepare aliquots if needed and avoid freeze–thaw.
• Allow vials to reach room temperature before opening to reduce condensation uptake.

Practical considerations for consistency and safety.

• Use new sterile insulin syringes; dispose in a sharps container.
• Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation^[12].
• Inject slowly; wait a few seconds before withdrawing the needle.
• Document daily dose and site rotation to maintain consistency.

Vesugen (KED) is a tripeptide derived from amino acids associated with vascular wall proteins^[1]. Research indicates it may support vascular endothelial cell proliferation by modulating the expression of Ki-67, a protein closely associated with cell division^[2]. The peptide is hypothesized to interact with promoter regions of the Ki-67 gene, potentially influencing epigenetic regulation^[3]. Additional studies suggest Vesugen may normalize endothelin-1 expression and increase sirtuin-1 (SIRT-1) expression in vascular endothelial cells^[4].

Observations from preclinical and cell culture research.

• May support vascular endothelial cell proliferation and renewal through Ki-67 gene regulation^[2][3].
• Research suggests potential neuroprotective properties; oral application improved memory and attention in elderly individuals with functional CNS disorders^[5].
• May restore synaptic plasticity in in vitro models of Alzheimer’s disease^[6].
• Generally well tolerated in reported studies; occasional mild injection-site reactions (redness/itch) may occur with subcutaneous administration.

Complementary strategies for best outcomes.

• Pair with a balanced, heart-healthy diet rich in antioxidants and omega-3 fatty acids.
• Combine regular cardiovascular exercise to reinforce vascular adaptations.
• Prioritize sleep and stress management to support recovery and cellular renewal.

General subcutaneous guidance from clinical best-practice resources^[11].

• Clean the vial stopper and skin with alcohol; allow to dry.
• Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue^[11][12].
• Do not aspirate for subcutaneous injections; inject slowly and steadily^[11].
• Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy^[12].

We recommend Pure Lab Peptides for high-purity Vesugen (20 mg).

Shop at Pure Lab Peptides

This content is for educational purposes only and is not medical advice.

• 1
  
  Bull Exp Biol Med (2016)
  — Short Peptides Regulate Gene Expression (Khavinson et al.)

  View Source
• 2
  
  Adv Gerontol (2014)
  — Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation during aging

  View Source
• 3
  
  Molecules (2021)
  — Peptide Regulation of Gene Expression: A Systematic Review (MDPI)

  View Source
• 4
  
  Adv Gerontol (2016)
  — Molecular aspects of vasoprotective peptide KED activity during atherosclerosis and restenosis

  View Source
• 5
  
  Bull Exp Biol Med (2021)
  — Peptide KED: Molecular-Genetic Aspects of Neurogenesis Regulation in Alzheimer’s Disease

  View Source
• 6
  
  Bull Exp Biol Med (2017)
  — Tripeptides Restore the Number of Neuronal Spines under Conditions of In Vitro Modeled Alzheimer’s Disease

  View Source
• 9
  
  DailyMed
  — Bacteriostatic Water injection, solution (FDA labeling)

  View Source
• 10
  
  PMC (2024)
  — Practical advice in the development of a lyophilized protein drug product

  View Source
• 11
  
  MedlinePlus
  — Subcutaneous (SQ) injections: technique and site guidance

  View Source
• 12
  
  NCBI Bookshelf
  — Best practices for injection (WHO guidelines)

  View Source
• 16
  
  Pure Lab Peptides
  — Vesugen (20 mg) product page (quality and batch documentation)

  View Source

Additional Research and Background

These sources provide related context and are not presented as support for a specific statement above.

• 1
  
  Int J Mol Sci (2022)
  — Neuroepigenetic Mechanisms of Action of Ultrashort Peptides in Alzheimer’s Disease

  View Source
• 2
  
  Pharmaceuticals (2021)
  — Neuroprotective Effects of Tripeptides-Epigenetic Regulators in Mouse Model of Alzheimer’s Disease

  View Source
• 3
  
  CDC
  — Vaccine administration: subcutaneous injection technique

  View Source
• 4
  
  Biogerontology (2010)
  — Peptide bioregulation of aging: Results and prospects (Anisimov & Khavinson)

  View Source
• 5
  
  Stem Cell Rev Rep (2020)
  — Peptide Regulation of Cell Differentiation

  View Source

Explore the available research context, protocol variants or comparisons, and practical guides. When vial-size variants exist, they remain separate because vial strength, concentration, and syringe-unit calculations can differ. Related compounds and blends are comparisons only, not interchangeable.